Taysha Gene Therapies, Inc. (TSHA) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.98B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Sean Nolan |
| IPO Date | 2020-09-24 | CAGR | — |
| Employees | 99 | Website | www.tayshagtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $2.00B | P/E | -16.29 | Forward P/E | -12.96 | PEG | — |
| P/S | 304.06 | P/B | 4.97 | P/CF | -14.55 | P/FCF | -12.3 |
| Sales | $5.49M | Sales 1Y | -32.27% | Sales 3Y | -42.88% | Sales 5Y | inf% |
| EPS | $-0.38 | EPS 1Y | 18.34% | EPS 3Y | -81.61% | EPS 5Y | -88.65% |
| Sales QoQ | — | EPS QoQ | 8.33% | Sales QoQ Avg | — | EPS QoQ Avg | 11.85% |
| Gross Margin | 83.96% | Operating Margin | -2792.32% | Profit Margin | -2728.04% | ROCE | -34.46% |
| ROA | -32% | ROE | -56% | Altman Z Score | 11.63 | Piotroski Score | 3 |
| Current Ratio | 17.76 | Quick Ratio | 17.76 | Cash Ratio | 17.53 | Op. CF Ratio | -1.56 |
| Debt/Equity | 0.02 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.02 | Lt Debt/Cap. | 0.02 |
| Intrst Cov. | -3646.64 | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $2.00B | P/E Ratio | -16.29 |
| Forward P/E | -12.96 | PEG Ratio | — |
| P/S Ratio | 304.06 | P/B Ratio | 4.97 |
| P/CF Ratio | -14.55 | P/FCF Ratio | -12.3 |
| EPS | $-0.38 | EPS Growth 1Y | 18.34% |
| EPS Growth 3Y | -81.61% | EPS Growth 5Y | -88.65% |
| Revenue Growth 1Y | -32.27% | Gross Margin | 0.84% |
| Operating Margin | -27.92% | Profit Margin | -27.28% |
| ROE | -0.56% | ROA | -0.32% |
| ROCE | -0.34% | Current Ratio | 17.76 |
| Quick Ratio | 17.76 | Cash Ratio | 17.53 |
| Debt/Equity | 0.02 | Interest Coverage | -3646.64 |
| Altman Z Score | 11.63 | Piotroski Score | 3 |
Taysha Gene Therapies, Inc. (TSHA) valuation & financials
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.98B and trades at a price-to-earnings ratio of -16.3. It operates in the Healthcare sector (Biotechnology).
Taysha Gene Therapies, Inc.'s revenue grew -32.3% over the last year.
Taysha Gene Therapies, Inc.'s next earnings report is scheduled for November 3, 2026 after market close; analysts estimate EPS of $-0.14. Check the earnings calendar to see all companies reporting this week.
Taysha Gene Therapies, Inc. (TSHA) — frequently asked questions
When does Taysha Gene Therapies, Inc. (TSHA) report earnings next?
Taysha Gene Therapies, Inc. is expected to report earnings on November 3, 2026 after market close. Analysts estimate EPS of $-0.14.
What is Taysha Gene Therapies, Inc.'s market cap?
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.98B.
What is TSHA's P/E ratio?
Taysha Gene Therapies, Inc. trades at a price-to-earnings ratio of -16.3, with trailing twelve-month EPS of $-0.38.
How fast is Taysha Gene Therapies, Inc. growing?
Taysha Gene Therapies, Inc.'s revenue grew -32.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)